ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2521

Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients

Shintaro Hirata1, Anthony Marotta2, Kentaro Hanami1 and Yoshiya Tanaka3, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Augurex Life Sciences Corp., Vancouver, BC, Canada, 3University of Occupational and Environmental Health, Kitakyushu, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, Rheumatoid arthritis (RA), tocilizumab and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Serum 14-3-3η is a mechanistic marker that is involved in the pathogenesis of RA and is a potent up-regulator of IL-6. We previously reported that baseline 14-3-3η levels were significantly lower in a cohort of 49 established RA patients who achieved better clinical outcomes when treated with Tocilizumab. Recently there has been increased interest in assessing therapy response using alternative measures to DAS that are independent of CRP, including patient reported outcomes such as HAQ-DI. The aim of this study was to validate whether lower baseline levels of 14-3-3η is associated with and independently predicts clinical response in RA patients treated with tocilizumab.

Methods: Serum 14-3-3η levels were measured in a cohort of 106 Japanese patients prior to the initiation of tocilizumab therapy (BL). 14-3-3η positivity was defined by the diagnostic cut-off of ≥ 0.19 ng/ml, and 2 and 4 times that, at 0.40 and 0.80 ng/ml, respectively. Patients were sub-grouped according to changes in HAQ-DI based on the minimal clinically important difference (MCID) of ≥ 0.22, ≥ 0.31, and ≥ 0.49. Group differences were assessed by Mann-Whitney U-test. ROC curve analysis was performed to identify the optimal 14-3-3η cut-point for a ΔHAQ-DI ≥ 0.49. Uni- and multi-variable analysis controlling for baseline HAQ-DI was used to assess 14-3-3η’s independence of other clinical/serological variables at informing patient reported outcomes.

Results: At baseline, 75 (71%) of the 106 patients were 14-3-3η positive. At year 1, 70 (66%), 58 (55%) and 52 (40%) of the 106 patients achieved changes in HAQ-DI of ≥ 0.22, ≥ 0.31, and ≥ 0.49, respectively. Baseline HAQ-DI values were significantly higher in those patients that achieved a Δ HAQ-DI ≥ 0.22 when compared with those that did not; p = 0.009. The HAQ-DI values were also significantly higher at the two other HAQ-DI cut-points (≥ 0.31, and ≥ 0.49), p < 0.0001. As shown in the Figure, serum 14-3-3η levels were significantly lower in patients that achieved HAQ-DI MCID of > 0.31 and >0 .49. In patients who achieved a ΔHAQ-DI ≥ 0.49, ROC analysis returned the best cut-off of ≤ 0.18 ng/ml yielding a specificity of 83.3% (95%CI: 70.7-92.1) and sensitivity of 42.3% (95%CI: 28.7-56.8), LR = 2.5. By univariate analysis, all three 14-3-3η cut-points were significantly associated with better clinical outcomes. Multi-variable modeling controlling for BL HAQ-DI indicated that lower levels of 14-3-3η, age and disease duration, but not CRP, were independent predictors of achieving the HAQ-DI MCID outcomes.    

 

14-3-3η positivity cut-off

 

≤ 0.19 ng/ml

≤ 0.40 ng/ml

≤ 0.80 ng/ml

 

LR

p-value

LR

p-value

LR

p-value

ΔHAQ > 0.22

6.75

0.0098

2.36

0.0950

0.94

0.2222

ΔHAQ > 0.31

9.57

0.0021

6.18

0.0114

3.56

0.0456

ΔHAQ > 0.49

8.61

0.0034

6.61

0.0090

3.88

0.0382

WR0

Conclusion: Lower serum 14-3-3η levels prior to the initiation of therapy independently predicts better patient reported outcomes in patients treated with tocilizumab. The predictive capacity of 14-3-3η at informing therapy response to anti-IL-6 therapy should be investigated across all anti-IL-6 compounds.


Disclosure: S. Hirata, None; A. Marotta, Augurex Life Sciences Corpt, 3; K. Hanami, None; Y. Tanaka, Bristol-Myers Squibb, MSD, Chugai, Mitsubishi-Tanabe, Astellas, AbbVie, Daiichi-Sankyo, 2,UCB Pharma, Mitsubishi-Tanabe, Abbott, AbbVie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GlaxoSmithKline, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei, 5.

To cite this abstract in AMA style:

Hirata S, Marotta A, Hanami K, Tanaka Y. Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/lower-baseline-14-3-3%ce%b7-levels-are-associated-with-better-patient-reported-outcomes-in-tocilizumab-treated-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lower-baseline-14-3-3%ce%b7-levels-are-associated-with-better-patient-reported-outcomes-in-tocilizumab-treated-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology